FAM75C1 Inhibitors
The chemical class of FAM75C1 Inhibitors comprises a variety of compounds that can potentially inhibit the activity of the FAM75C1 protein, either directly or indirectly. FAM75C1 is likely involved in cellular processes regulated by signaling pathways such as the epidermal growth factor receptor (EGFR), RAF/MEK/ERK, histone deacetylase (HDAC), and others.
Direct inhibitors such as gefitinib, selumetinib, vorinostat, ruxolitinib, enzalutamide, idelalisib, trametinib, axitinib, imatinib, alectinib, and dasatinib target specific kinases or enzymes involved in these pathways, potentially disrupting cellular processes that rely on FAM75C1 function. Indirect inhibitors exert their effects by modulating signaling cascades that intersect with FAM75C1-mediated pathways, ultimately influencing the activity of FAM75C1. These inhibitors provide valuable tools for investigating the physiological roles of FAM75C1 and may have implications in diseases where dysregulation of FAM75C1-associated pathways occurs.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is a tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR). By inhibiting EGFR, gefitinib disrupts downstream signaling pathways, potentially influencing cellular processes regulated by FAM75C1. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Selumetinib is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the RAF/MEK/ERK signaling pathway. Inhibition of MEK by selumetinib can disrupt signaling cascades involved in cellular processes regulated by FAM75C1. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Vorinostat is a histone deacetylase (HDAC) inhibitor that modulates gene expression by altering chromatin structure. Its effects on gene regulation may indirectly influence cellular processes regulated by FAM75C1. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib is a Janus kinase (JAK) inhibitor used for myeloproliferative disorders. By inhibiting JAK, ruxolitinib can disrupt cytokine signaling pathways, potentially affecting cellular processes regulated by FAM75C1. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $240.00 $1030.00 | 7 | |
Enzalutamide is an androgen receptor inhibitor used for prostate cancer. It blocks the androgen receptor, disrupting androgen signaling pathways that may intersect with cellular processes regulated by FAM75C1. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $189.00 | 4 | |
Idelalisib is a phosphoinositide 3-kinase (PI3K) inhibitor that disrupts PI3K signaling pathways involved in cell survival and proliferation. Inhibition of PI3K by idelalisib may indirectly influence cellular processes regulated by FAM75C1. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a selective inhibitor of MEK1 and MEK2, key components of the RAF/MEK/ERK signaling pathway. Inhibition of MEK by trametinib can disrupt downstream signaling cascades involved in cellular processes regulated by FAM75C1. | ||||||
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $44.00 $109.00 | 61 | |
Imatinib is a tyrosine kinase inhibitor targeting BCR-ABL, c-KIT, and PDGFR. Inhibition of these kinases by imatinib can disrupt signaling pathways involved in cellular processes regulated by FAM75C1. | ||||||
CH5424802 | 1256580-46-7 | sc-364461 sc-364461A | 5 mg 50 mg | $191.00 $902.00 | ||
Alectinib is a tyrosine kinase inhibitor targeting anaplastic lymphoma kinase (ALK). By inhibiting ALK, alectinib disrupts downstream signaling pathways, potentially influencing cellular processes regulated by FAM75C1. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a multi-targeted kinase inhibitor that blocks the activity of BCR-ABL, SRC family kinases, c-KIT, and PDGFR. Inhibition of these kinases by dasatinib can interfere with signaling pathways involved in cellular processes regulated by FAM75C1. | ||||||